AMA CEO warns of 'digital dystopia' at AMA meeting

American Medical Association Executive Vice President and CEO James L. Madara, MD, said physicians need to have a role in the creation of new digital products as a way to ensure the industry stays away from what he calls a “digital dystopia” of technology that makes care less efficient, and going as far as to say digital tools seem to work effectively in "almost any other field" except medical practice. 

Speaking at the AMA's annual meeting in Chicago, Madara also talked about the good side of advanced medical technology, like robotic surgery, and the AMA's own initiatives like their Silicon Valley "innovation studio," Health 2047, and MATTER, an incubator based in Chicago aimed at helping start-up medical technology companies. 

But his focus was on instances where digital products only created frustration for physicians. 

“Appearing in disguise among these positive products are other digital so-called advancements that don’t have an appropriate evidence base … or that just don’t work well or that actually impede care, confuse patients and waste our time,” he said, “from ineffective electronic health records (EHR) to an explosion of direct-to-consumer digital health products to apps, some of which are of poor quality.”

The "digital dystopia" could be avoided, Madara said, by physicians being more closely involved in the development of new technology. At MATTER, he said the AMA has had success in having physicians talk directly to entrepeneurs about what their practices need. 

“We do much better if new products and services are deeply informed by our actual problems and needs,” he said.

By being directly involved, Madara believes medical professionals can make sure the new technology helps, rather than hinders, the patient-phyiscian relationship. 

"What we don't need is more digital snake oil," he said. 

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.